AIM ImmunoTech partners with Thermo Fisher to design Phase 3 trial for Ampligen in pancreatic cancer, while Innovent Biologics begins dosing patients in Phase 3 study of IBI354 for HER2-positive breast cancer.
AIM ImmunoTech outlined key milestones for its Phase 2 DURIPANC trial evaluating Ampligen combined with durvalumab in metastatic pancreatic cancer, with primary endpoint evaluation expected in December 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07773545 |
The Effect of Visual Patient Education on Helmet Use Behaviour in Elderly Patients After a Bicycle, E-bike, or Moped Accident |
ACTIVE_NOT_RECRUITING | NA |
| NCT07772544 |
Prevention of Psoriatic Arthritis Inflammation Through Digital Care: A Feasibility Mixed-Methods Study |
NOT_YET_RECRUITING | NA |
| NCT07743762 |
Percutaneous Versus EUS-guided Drainage of Symptomatic Fluid Collections After Left Pancreatectomy |
NOT_YET_RECRUITING | NA |
| NCT07727603 |
Global AI Governance: Maturity and Implementation in Leading Hospitals for Responsible AI in Healthcare |
ENROLLING_BY_INVITATION | |
| NCT07715968 |
The Turbine-based CO2 Insufflator Pediatric Feasibility Study |
RECRUITING | NA |
| NCT07692295 |
Biomarkers for Post-treatment Control in HIV: International Study of the EU2Cure Research Consortium (Phase I) |
NOT_YET_RECRUITING | |
| NCT07690618 |
Thermotherapy for Head and Neck Cancer Patients |
NOT_YET_RECRUITING | PHASE1 |
| NCT07674537 |
Bilirubin Thresholds in Preterm Infants on Neonatal Intensive CarE Units: The B-NICE Trial |
NOT_YET_RECRUITING | NA |
| NCT07668856 |
Cannabidiol as add-on Therapy for Children With Refractory Epilepsy (CBD-uN1que), a High-quality Individualized Approach: a Series of N-of-1 Trials |
RECRUITING | PHASE3 |
| NCT07651748 |
Secretin in Ex-situ Liver Perfusion |
ENROLLING_BY_INVITATION | PHASE1/PHASE2 |
